•
Jun 30, 2020
Phathom Q2 2020 Earnings Report
Phathom reported a net loss, increased R&D and G&A expenses, and maintained a strong cash position.
Key Takeaways
Phathom Pharmaceuticals reported a net loss of $21.1 million for the second quarter of 2020. The company resumed patient screening and enrollment in Phase 3 trials for vonoprazan and continued to build its organization. R&D and G&A expenses increased due to clinical trial costs and the buildout of administrative and commercial functions. Cash and cash equivalents were $247.3 million as of June 30, 2020.
Resumed patient screening and enrollment in PHALCON-EE and PHALCON-HP Phase 3 trials.
Expect topline data for both HP and EE trials in 2021.
Strengthened Executive Leadership Team with the appointment of Todd Branning as CFO.
Second quarter net loss was $21.1 million.